Directory → Neurotropic funds → Neiroleptiki
This page is translated automatically with a help of Google Translate
The groupThe neuroleptic of funds intended for the treatment of psychoses and other severe mental disorders. The group neirolepticakih drugs is a derivative fenotiazina (chlorpromazine, etc.), butirofenona (haloperidol, droperidol, etc.), derivatives дифенилбутилпипериди на (fluspirilen etc.), etc.
Neiroleptiki have multiple effects on the body. The main pharmacological characteristics of the kind of soothing, with a decrease in responses to external stimuli, weakening psychomotor stimulation and emotional tension, repression of the fear of the weakening of aggressiveness. They can suppress delirium, hallucinations, automaticity and other mental disorders, and to provide medical effects in patients with schizophrenia and other mental illnesses.
Expressed by the old neiroleptiki in normal doses do not, but can cause dremotnoe state bring the sleep and strengthen the influence pills and other sedatives (sedative) funds. They potenziruut of drugs, analgesics and local anaesthetics and weaken effects psychoactive drugs.
Those doses antipsihoticescoe by the sedative effect (aliphatic derivatives fenotiazina : chlorpromazine, promazin, levomepromazin, etc.) and others (pieperazinove derivatives fenotiazina : Prochlorperazine, trifluoperazin, etc.; some butirofenona) aguirutm (energezirutm). Some neiroleptiki weaken depression.
The physiological mechanisms of the central doses is essential to the braking retikuliarna brain structures and the weakening of its aguirutego influence on the crust large hemispheres. Various doses effects associated with exposure to the emergence and the commencement of the different levels of the central and peripheral nervous system.
Neiroleptiki neurochemical changes (mediator) processes in the brain : dofaminergicakie, adrenergicakie, serotoninergicakie, Gamkergicakie, holinergicakie, neiropeptidnye and others. Various doses and individual drugs differ on the impact on education, stockpiling, release and metabolism neiromediatorov and their interaction with receptors in different brain structures, that significantly affects their therapeutic and pharmacological properties.
Neiroleptiki different groups (fenotiazina, butirofenona etc.) blocking dofaminove (D_2) receptors of the brain structures. We assume that this is mainly antipsihoticescuu activity, while oppression central noradrainergicakih receptors (in particular, retikuliarna in formation), only sedativuyu. The oppression mediator release activity linked to a large extent, not only antipsihoticescoe influence doses, but due to their neirolepticeski syndrome (ekstrapiramidnye disorders) 1,264,400 blockade dofaminergicakih subcortical structures entities cord (black substance and polostoe body bugornaya, mejlimbical and mezokorticalnaya field) located where large numbers dofamine receptors.
The impact on the central dofaminove receptors leads to some endocrine violations caused neiroleptikami. Dofaminove blocking receptors glands, they increased secretion of prolactin and stimulate lactation, and acting dystonia hindering the secretion kortikotropina and somatotroponogo hormone.
Neiroleptikom to the concerns antipsihoticescoy activity, but little of ekstrapiramidnyi side effects is klozapin-derivative пиперазино-дибензоди��зепина. This feature product in it antiholinergicakimi properties.
Most doses are absorbed by the different ways of (inwards injection), crosses the GEB, but accumulates in the brain in much smaller quantities than the internal organs (liver, lung), metabolised in the liver, and presented with urine, partially-intestinal. They have a relatively short period of half-and after a single act of a short time. A prolongirovanne drugs (ftorfenazin-dekanoat, fluspirilen, pimozid etc.), with an introduction Injecting or ingestion lasting effect.